ReviewNPJ precision oncology2019
Cancer prevention and screening: the next step in the era of precision medicine.
Review in NPJ precision oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 100 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
100 citing papers in PubMed, 2 syntheses or guidelines pooled it, 203 citations in OpenAlex.
- Altered Food Behavior and Cancer: A Systematic Review of the Literature.International journal of environmental research and public health · 2022Pooled it
- Association Between Environmental and Socioeconomic Risk Factors and Hepatocellular Carcinoma: A Meta-Analysis.Frontiers in public health · 2022Pooled it
- Comparative performance of biopolymer-supported graphitic carbon nitride nanosheets for electrochemical carcinoembryonic antigen cancer biomarker detection in serum samples using smartphone device.Mikrochimica acta · 2026Article
- Impact of tumor budding on recurrence risk prediction in stage I-III colorectal cancer: a Swedish cohort study.American journal of clinical pathology · 2026Article
- The Microbiome-Mitochondria-Extracellular Vesicle Axis in HPV Persistence and Cervical Carcinogenesis.Genes · 2026Review
- Copy Number Alterations in Canine Urothelial Carcinomas: The Impact of Tumour Purity.Veterinary sciences · 2026Article
- Predictive Biomarkers for Asymptomatic Adults: Opportunities, Risks, and Guidance for General Practice.Diagnostics (Basel, Switzerland) · 2026Review
- Knowledge and Awareness of Cancer Screening Among the Public in Saudi Arabia: A Cross-Sectional Study.Cureus · 2026Article
- Endometrial Hyperplasia: Current Insights into Epidemiology, Risk Factors, and Clinical Management.Cancers · 2025Review
- E2F transcription factors as multimodal biomarkers for pan-cancer management.Scientific reports · 2025Article
- p53 prophylactic therapy for cancer prevention.Cell death and differentiation · 2025Article
- Precision Oncology: Current Landscape, Emerging Trends, Challenges, and Future Perspectives.Cells · 2025Review
- Assessment of Gaps and Inequalities in Cancer Screening at the District Level in Peru.Epidemiologia (Basel, Switzerland) · 2025Article
- Expanding Cancer Prevention: Strategies Integrated into Occupational Health Surveillance.Cancers · 2025Review
- Impact of Neighborhood Socioeconomic Trajectories on Gastrointestinal Cancer Care: A SEER-Medicare Analysis.Annals of surgical oncology · 2025Article
- Knowledge, attitudes, and practices of liver cancer screening among high-risk populations in China.BMC public health · 2025Article
- Genes driving three-dimensional growth of immortalized cells and cancer.Cell death & disease · 2025Article
- Interventions to improve oral endocrine therapy adherence in breast cancer patients.Journal of cancer survivorship : research and practice · 2025Review
- Beyond Transposons:Genes · 2025Article
- Risk prediction of second primary malignancies in patients with primary gastric neuroendocrine neoplasms: a population-based study.Discover oncology · 2025Article
40 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A primary mode of cancer prevention and early detection in the United States is the widespread practice of screening. Although many strategies for early detection and prevention are available, adverse outcomes, such as overdiagnosis and overtreatment, are prevalent among those utilizing these approaches. Broad use of mammography and prostate cancer screening are key examples illustrating the potential harms stemming from the detection of indolent lesions and the subsequent overtreatment. Furthermore, there are several cancers for which prevention strategies do not currently exist. Clinical and experimental evidence have expanded our understanding of cancer initiation and progression, and have instructed the development of improved, precise modes of cancer prevention and early detection. Recent cancer prevention and early detection innovations have begun moving towards the integration of molecular knowledge and risk stratification profiles to allow for a more accurate representation of at-risk individuals. The future of cancer prevention and early detection efforts should emphasize the incorporation of precision cancer prevention integration where screening and cancer prevention regimens can be matched to one's risk of cancer due to known genomic and environmental factors.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.